Trial Profile

Separate China Phase 1 study of MSB-2311 with several disease expansion cohorts

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MSB 2311 (Primary)
Indications Cancer
Focus Therapeutic Use

Most Recent Events

17 Apr 2018 New trial record
13 Apr 2018 According to a MabSpace Biosciences media release, this study i9s at the final stage of regulatory review, and is expected to be initiated soon upon CFDA approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com